novadigm.net valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | NovaDigm |
| Description | Home Contact About Us Overview Executive Team Board of Directors Scientific Founders News and Events Careers Development Programs Overview Vulvovaginal Ca |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 107.180.1.226 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
novadigm.net Valuation
|
US$613,599
Last updated: 2023-05-09 09:24:50
novadigm.net has Semrush global rank of 17,249,546. novadigm.net has an estimated worth of US$ 613,599, based on its estimated Ads revenue. novadigm.net receives approximately 70,800 unique visitors each day. Its web server is located in United States, with IP address 107.180.1.226. According to SiteAdvisor, novadigm.net is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$613,599 |
| Daily Ads Revenue | US$567 |
| Monthly Ads Revenue | US$16,992 |
| Yearly Ads Revenue | US$203,904 |
| Daily Unique Visitors | 4,720 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| novadigm.net. | A | 7199 | IP: 107.180.1.226 |
| novadigm.net. | NS | 3600 | NS Record: ns69.domaincontrol.com. |
| novadigm.net. | NS | 3600 | NS Record: ns70.domaincontrol.com. |
| novadigm.net. | MX | 3600 | MX Record: 0 novadigm-net.mail.protection.outlook.com. |
| novadigm.net. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
HtmlToTextCheckTime:2023-05-09 09:24:50
| Home Contact About Us Overview Executive Team Board of Directors Scientific Founders News and Events Careers Development Programs Overview Vulvovaginal Candidiasis Future Indications Patients About Vulvovaginal Candidiasis Clinical Trials Patient Questions and Glossary Science Overview Medical Need Overview Candida Staphylococcus aureus NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in some cases, life-threatening. NovaDigm’s lead development candidate, NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida , including nosocomial candidiasis, a severe life threatening infection and Staphylococcus aureus , including MRSA. Terms of Use |
HTTP Headers
HTTP/1.1 200 OK Date: Sun, 31 Oct 2021 15:41:05 GMT Server: Apache Upgrade: h2,h2c Connection: Upgrade Last-Modified: Wed, 18 Apr 2018 21:29:23 GMT ETag: "b7600f1-1b66-56a26260df163" Accept-Ranges: bytes Content-Length: 7014 Vary: Accept-Encoding Content-Type: text/html |
novadigm.net Whois Information
Domain Name: NOVADIGM.NET Registry Domain ID: 669550398_DOMAIN_NET-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2021-03-27T19:51:56Z Creation Date: 2006-11-13T20:50:13Z Registry Expiry Date: 2024-03-26T11:59:59Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS69.DOMAINCONTROL.COM Name Server: NS70.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-19T01:18:33Z <<< |